Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jul 8:366:l4179.
doi: 10.1136/bmj.l4179.

Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials

Qi Feng  1 , Aoshuang Zhou  1 , Huachun Zou  2   3 , Suzanne Ingle  4 , Margaret T May  4 , Weiping Cai  5 , Chien-Yu Cheng  6   7 , Zuyao Yang  8 , Jinling Tang  1   9
Affiliations
Meta-Analysis

Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials

Qi Feng et al. BMJ. .

Abstract

Objective: To evaluate the effects of four drug (quadruple) versus three drug (triple) combination antiretroviral therapies in treatment naive people with HIV, and explore the implications of existing trials for clinical practice and research.

Design: Systematic review and meta-analysis of randomised controlled trials.

Data sources: PubMed, EMBASE, CENTRAL, Web of Science, and the Cumulative Index to Nursing and Allied Health Literature from March 2001 to December 2016 (updated search in PubMed and EMBASE up to June 2018); and reference lists of eligible studies and related reviews.

Study selection: Randomised controlled trials comparing quadruple with triple combination antiretroviral therapies in treatment naive people with HIV and evaluating at least one effectiveness or safety outcome.

Review methods: Outcomes of interest included undetectable HIV-1 RNA, CD4 T cell count, virological failure, new AIDS defining events, death, and severe adverse effects. Random effects meta-analyses were conducted.

Results: Twelve trials (including 4251 people with HIV) were eligible. Quadruple and triple combination antiretroviral therapies had similar effects on all relevant effectiveness and safety outcomes, with no point estimates favouring quadruple therapy. With the triple therapy as the reference group, the risk ratio was 0.99 (95% confidence interval 0.93 to 1.05) for undetectable HIV-1 RNA, 1.00 (0.90 to 1.11) for virological failure, 1.17 (0.84 to 1.63) for new AIDS defining events, 1.23 (0.74 to 2.05) for death, and 1.09 (0.89 to 1.33) for severe adverse effects. The mean difference in CD4 T cell count increase between the two groups was -19.55 cells/μL (-43.02 to 3.92). In general, the results were similar, regardless of the specific regimens of combination antiretroviral therapies, and were robust in all subgroup and sensitivity analyses.

Conclusion: In this study, effects of quadruple combination antiretroviral therapy were not better than triple combination antiretroviral therapy in treatment naive people with HIV. This finding lends support to current guidelines recommending the triple regimen as first line treatment. Further trials on this topic should be conducted only when new research is justified by adequate systematic reviews of the existing evidence. However, this study cannot exclude the possibility that quadruple cART would be better than triple cART when new classes of antiretroviral drugs are made available.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure forms at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; MTM received grants from NIAAA US and NIHR HPRU UK; HZ received grants from the National Science Foundation of China Young Scientist Fund (81703278), National Science and Technology Major Project (China; 2018ZX10721102), Sanming Project of Medicine (Shenzhen; SZSM201811071), and Australian National Health and Medical Research Council Early Career Fellowship (APP1092621); the other authors had no financial relationships with any organisations that might have an interest in the submitted work in the precious three years; no other relationship or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
The flowchart of study selection
Fig 2
Fig 2
Meta-analysis of comparative effects between quadruple and triple combination antiretroviral therapies (cART) as first line treatment for people with HIV, on undetectable HIV-1 RNA
Fig 3
Fig 3
Meta-analysis of comparative effects between quadruple and triple combination antiretroviral therapies (cART) as first line treatment for people with HIV, on increase in CD4 T cell count (cells/μL). SD=standard deviation
Fig 4
Fig 4
Meta-analysis of comparative effects between quadruple and triple combination antiretroviral therapies (cART) as first line treatment for people with HIV, on virological failure
Fig 5
Fig 5
Meta-analysis of comparative effects between quadruple and triple combination antiretroviral therapies (cART) as first line treatment for people with HIV, on new AIDS defining events
Fig 6
Fig 6
Meta-analysis of comparative effects between quadruple and triple combination antiretroviral therapies (cART) as first line treatment for people with HIV, on death
Fig 7
Fig 7
Meta-analysis of comparative effects between quadruple and triple combination antiretroviral therapies (cART) as first line treatment for people with HIV, on severe adverse effects
None
See this image and copyright information in PMC

References

    1. GBD 2016 Causes of Death Collaborators Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151-210. 10.1016/S0140-6736(17)32152-9. - DOI - PMC - PubMed
    1. World Health Organization. Summary of the global HIV epidemic (2017). https://www.who.int/hiv/data/en/ Accessed 05 Dec 2018.
    1. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis 2013;208:224-34. 10.1093/infdis/jit150. - DOI - PMC - PubMed
    1. Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9. 10.1016/S0140-6736(08)61113-7. - DOI - PMC - PubMed
    1. Jin Y, Liu Z, Wang X, et al. A systematic review of cohort studies of the quality of life in HIV/AIDS patients after antiretroviral therapy. Int J STD AIDS 2014;25:771-7. 10.1177/0956462414525769. - DOI - PubMed

MeSH terms